OTEZLA IMPROVES SYMPTOMS WITHIN 2 WEEKS OF TREATMENT1
OTEZLA monotherapy improves ACR20 response as early as week 21,2,a,b
aACTIVE study. Data as observed.
bThe placebo/OTEZLA 30 mg BID crossover group includes patients who were randomized to placebo at baseline and switched to OTEZLA 30 mg BID at week 16 or week 24. In the full analysis set: OTEZLA, n = 110; placebo, n = 109. The n at each time point represents the number of patients with available data at the time point.
OTEZLA monotherapy delivers rapid and sustained efficacy in psoriatic arthritis1,2
OTEZLA monotherapy improves symptoms of psoriatic arthritis as early as week 2, with continuous improvement up to 1 year1:
- Tender and swollen joints: At 1 year, patients taking OTEZLA 30 mg BID achieved a 77.5% reduction in SJC and a 70.4% reduction in TJC
- Enthesitis: At week 2, patients with preexisting enthesitis experienced significant improvement with OTEZLA 30 mg BID vs placebo (-1.1 vs -0.4 mean change in GEI; P < 0.05); at 1 year, 69.8% of patients taking OTEZLA 30 mg BID from baseline achieved complete resolution of enthesitis
- Physical function: HAQ-DI score was significantly improved at week 2 with OTEZLA 30 mg BID vs placebo (-0.13 vs -0.05; P < 0.05) with a mean reduction from baseline HAQ-DI score of -0.40 at 1 year
ACR, American College of Rheumatology; ACTIVE, Accessing Apremilast Monotherapy in a Clinical Trial of Biologic-Naïve Patients with Psoriatic Arthritis; BID, twice daily; GEI, Gladman Enthesitis Index; HAQ-DI, Health Assessment Questionnaire–Disability Index; SJC, swollen joint count; TJC, tender joint count.
- Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheumatol. 2018 Jan 17 doi: 10.1136/annrheumdis-2017-211568 [Epub ahead of print].
- Data on file, Celgene Corporation.